An oral pharmaceutical composition which comprises a polyglycerol ester of an unsaturated fatty acid and a drug which is very slightly soluble in water.

Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

A vacuum regulator control for maintaining a predetermined partial vacuum in a milking circuit has an L-shaped linkage lever that is fulcrumed adjacent the juncture of the upright leg and the horizontal leg of the lever. A ball valve is suspended from a pivot point near the upper end of the upright leg so that the valve can seat when the lever pivots on the fulcrum, and prevent ambient pressure from entering the circuit. When the vacuum drops below the desired amount, the valve is drawn downward...

A nonsteroidal anti-inflammatory drug which is phenylacetic acid derivative and methods of using the same in topically controlling eye inflammations.

Novel diethylene glycol monoester of antirheumatically effective acids, e.g., lonazolac and diclofenac and others are disclosed which have inflammation inhibitory properties superior to the corresponding acid base forms. They may be produced through direct esterification without elimination of water and are suitable in the fight against diseases of the rheumatic complex.

Novel compounds of formula ##STR1## are described which have antipyretic, analgesic and antiinflammatory activity. R is hydrogen, C.sub.1 -C.sub.3 linear or branched alkyl; R.sub.1 and R.sub.2 are hydrogen, halogen, unsubstituted or esterified hydroxy, alcoxy, and may be the same or different; R.sub.3 is hydrogen, C.sub.1 -C.sub.4 linear or branched aliphatic acyl, unsubstituted or substituted aroyl, alkylaroyl or hetaroyl groups.

The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba, and ginger, and synthetic chemical analogues thereof, for the treatment of a beta-Amyloid protein-induced disease.

An external preparation characterized by comprising, as selected from gallic acid derivatives of the following formula (I), ##STR00001## wherein R.sup.1 represents a hydrogen atom, an alkali metal, an alkaline earth metal, an ammonium salt, or an alkyl or alkenyl group having from 1 to 18 carbon atoms and R.sup.2, R.sup.3, and R.sup.4 independently represent a hydrogen atom, an hydroxyl group, an alkoxy group having from 1 to 18 carbon atoms, a polyoxyethylene group, a polyoxypropylene group, or...

The present invention provides a novel crystalline form of n-butyl[4-[2-[2-hydroxy-5-(N-hydroxycarbamimidoyl) benzenesulfonylamino]ethyl]-2'-methanesulfonyl-3-yloxy] acetate hydrochloride, pharmaceutical compositions containing the same and their uses, which exhibits excellent inhibitory activities against activated blood coagulation factor X, and is useful for the treatment or prevention of a tromboembolic disease.

The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba, and ginger, and synthetic chemical analogues thereof, for the treatment of a beta-Amyloid protein-induced disease.